The week's loudest signal is consumer reconnaissance on GLP-1 brands. Wikipedia pageviews for Zepbound rose 39% week-over-week and Mounjaro climbed 36%, pushing both to the top of the Emerging Demand Index at scores of 1.89 and 1.73. With no FDA action or news catalyst behind the move, this looks like organic patient-side research — the kind that precedes consult requests by two to four weeks.

Emerging Demand — What to Watch

  • Zepbound (EDI 1.89, Weight Loss): Wikipedia traffic +39% WoW with no offsetting trials or FDA shift. Pure attention signal — brand-name research, not generic curiosity.
  • Mounjaro (EDI 1.73, Weight Loss): Wikipedia traffic +36% WoW, mirroring Zepbound. The parallel move suggests a category-wide pull rather than a single-brand news event.
  • Long COVID (EDI 1.45, Pulmonology): Wikipedia pageviews +49% WoW against only 1 new recruiting trial in the last 30 days. The research pipeline is cooling while public interest re-accelerates — a divergence worth watching for symptom-clinic demand.
  • Obesity (EDI 0.28, Bariatrics): Wiki traffic flat (+1%), but 21 new recruiting trials in 30 days signal sustained sponsor investment that will pull patients into screening funnels.
  • Anxiety (EDI 0.27, Psychiatry): Wiki flat, but 24 new recruiting trials — the highest trial velocity in the index. Behavioral health operators should expect study-driven referral inbound.

Search Intent

Google Trends returned no rising or falling national breakouts this week, which makes the Wikipedia-driven EDI signal the cleanest read available. The absence of a confirming search spike on GLP-1s suggests the 37%+ Wikipedia lift is still in the research phase — patients learning before they search for prescribers. Expect coincident Google query volume to catch up over the next 10–14 days.

Structural Markets

Arkansas remains the most structurally underserved state in the index, posting hypertension prevalence of 42.5% versus a 34% national rate — an 8.5-point gap that compounds with elevated obesity (38.9% vs 34.3%), depression (25.2% vs 21.7%), and COPD (9.6% vs 6.3%). Operators with cardiometabolic or pulmonary capacity in AR are sitting on the largest unmet-need delta in the country. Michigan and Ohio both run roughly 5 points above national on depression (26.7% and 26.6% vs 21.7%), reinforcing the Midwest behavioral-health thesis as trial recruitment accelerates.

Respiratory Watch

Respiratory season is unwinding cleanly. Influenza is falling across 82 of 82 reporting HSAs in Texas, 81 of 81 in Georgia, and 63 of 63 in Michigan, and RSV is falling in 52 of 52 Texas HSAs and 39 of 39 in New York. Urgent care and pediatric operators can begin reallocating respiratory capacity now.

The Bottom Line

Front-load GLP-1 ad spend and consult capacity this week — the 37%+ Wikipedia lift on Zepbound and Mounjaro is a two-to-four week leading indicator that has not yet shown up in search. Bariatric and behavioral health operators should prepare for trial-driven referral volume, especially in Arkansas and the Midwest. Respiratory staffing can stand down.